Navigation Links
Drug therapy reduces neuroblastoma tumor growth in pre-clinical investigation

SAN DIEGO - Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have discovered a new drug combination that significantly hinders tumor growth in neuroblastoma, a childhood cancer. The study was presented today at the 22nd annual meeting of the American Society of Pediatric Hematology/Oncology (ASPHO).

By combining a novel multi-kinase inhibitor, vandetanib, with 13-cis-retinoic acid (CRA), a drug often used for severe acne, researchers from the Children's Cancer Hospital at M. D. Anderson found that the two therapies reduced neuroblastoma tumors by 86 percent in pre-clinical tests.

Peter Zage, M.D., Ph.D., who specializes in neuroblastoma at the Children's Cancer Hospital, received this year's Young Investigator Award from ASPHO and was selected to present his research today in a special platform session.

"By itself, vandetanib inhibited tumor growth by two-thirds and decreased blood vessel formation around neuroblastoma tumors in mice," says Zage. "When combined with CRA, the impact was even greater on tumor growth."

Vandetanib blocks a family of endothelial growth factors and receptors that promote tumor growth as well as the RET oncogene, which can signal neuroendocrine cells to develop into neuroblastoma cells. Although commonly used in treatment for neuroblastoma, CRA by itself does not have a significant impact against the childhood cancer. However, it works in combination therapy to differentiate neuroblastoma cells into mature benign neural cells.

Currently, there is a Phase I clinical trial open for children with multiple-relapsed neuroblastoma to further study the new therapy combination. This trial is the first in the world to test vandetanib in children.

Zage says in addition to the pediatric patients enrolled in the Phase I trial, adult patients with lung cancer have received vandetanib and have tolerated the novel drug well.

According to the American Cancer Society, approximately 650 children, mainly under the age of five, are diagnosed with neuroblastoma in the United States each year. Close to two-thirds of these children are diagnosed after the cancer has metastasized to other parts of the body. For these patients with high-risk neuroblastoma, long-term survival is less than 40 percent because the tumors are often resistant to traditional chemotherapy.


Contact: Lindsay Anderson
University of Texas M. D. Anderson Cancer Center

Related medicine news :

1. Vision restoration therapy shown to improve brain activity in brain injured patients
2. HIV therapy in pregnancy-data support WHO recommendations
3. Family-based treatment more effective than supportive psychotherapy in treating bulimia
4. Trial to Test Gene Therapy for Angina in Women
5. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
6. Aromatherapy Gift Line Sheds Humorous Light on Modern Therapy
7. Chemotherapy may be culprit for fatigue in breast cancer survivors
8. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
9. New Drug No Substitute for Standard Blood-Clot Therapy
10. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
11. Nucletron Announces Management Buy-Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community
Post Your Comments:
Related Image:
Drug therapy reduces neuroblastoma tumor growth in pre-clinical investigation
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: